Publications

2024

Bava CI, Valentino P, Malucchi S, Bottero R, Martire S, Sapio AD, Bertolotto A.  Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions.  Mult Scler Relat Disord. 2024 Jun 29;88:105748. doi: 10.1016/j.msard.2024.105748. 

2022

Valentino P, Malucchi S, Martire S, Bava CI, Capobianco MA, Bertolotto A (2022).  sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients.  Mult Scler Relat Disord. 67:104176. doi: 10.1016/j.msard.2022.104176  

Montarolo F, Martire S, Chiara F, Allegra S, De Francia S, Hoxha E, Tempia F, Capobianco MA, Bertolotto A. (2022)  NURR1-deficient mice have age- and sex-specific behavioral phenotypes.  J Neurosci Res. 100(9):1747-1754. doi: 10.1002/jnr.25067 

Balbo I, Montarolo F, Genovese F, Tempia F, Hoxha E. (2022)  Effects of the administration of Elovl5-dependent fatty acids on a spino-cerebellar ataxia 38 mouse model. Behav Brain Funct.  18(1):8. doi: 10.1186/s12993-022-00194-4 

Martire S, Valentino P, Marnetto F, Mirabile L, Capobianco MA, Bertolotto A. (2022)  The impact of pre-freezing storage time and temperature on gene expression of blood collected in EDTA tubes.  Mol Biol Rep. doi: 10.1007/s11033-022-07320-5 

Montarolo F, Martire S, Marnetto F, Valentino P, Valverde S, Capobianco MA, Bertolotto A. (2022)  The Selective Agonist for Sphingosine-1-Phosphate Receptors Siponimod Increases the Expression Level of NR4A Genes in Microglia Cell Line.  Curr. Issues Mol. Biol. 44, 1247-1256.  https://doi.org/10.3390/cimb44030083

2021

Valentino P, Marnetto F, Martire S, Malucchi S, Bava CI, Popovic M, Bertolotto A (2021)  Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice .   MultSclerRelatDisord  54:103090. Jun.Doi: 10.1016/j.msard.2021.103090.

Furlan C, Montarolo F, Di Gregorio E, Parolisi R, Atlante S, Buffo A, Bertolotto A, Aime S, Gianolio E.J  Analysis of the Gadolinium retention in the Experimental Autoimmune Encephalomyelitis (EAE) murine model of Multiple Sclerosis.   Trace Elem Med Biol. 2021 Aug 2;68:126831. doi: 10.1016/j.jtemb.2021.126831. Online ahead of print. PMID: 34364067

Eriola Hoxha, Ilaria Balbo, Roberta Parolisi, Matteo Audano, Francesca Montarolo, Francesco Ravera, Michela Guglielmotto, Luisa Muratori, Stefania Raimondo, Eleonora Di Gregorio, Annalisa Buffo, Alfredo Brusco, Barbara Borroni, Nico Mitro, Donatella Caruso, Filippo Tempia (2021)  Elovl5 is required for proper action potential conduction along peripheral myelinated fibers.  Glia. 17 June 2021  https://doi.org/10.1002/glia.24048  

Ilaria Balbo, Francesca Montarolo, Enrica Boda, Filippo Tempia and Eriola Hoxha (2021)  Elovl5 Expression in the Central Nervous System of the Adult Mouse.   Front. Neuroanat., 29 April 2021  doi.org/10.3389/fnana.2021.669073

Martire S, Montarolo F, Spadaro M, Perga S, Sforza M.L, Marozio L, Frezet F, Bruno S, Chiabotto G, Deregibus M.C, Camussi G, Botta G, Benedetto C, Bertolotto A (2021)  A First Phenotypic and Functional Characterization of Placental Extracellular Vesicles from Womenwith Multiple Sclerosis . Int. J. Mol.Sci. 2021, 22, 2875.  https://doi.org/10.3390/ijms22062875

Bandettini di Poggio M, Toni D, Gandolfo C, Paolicelli D, Zini A, Agostoni E, Bandini F, Ragno M, Altavista MC, Bertolotto A, Siciliano G, Vecchio M, Tambasco N, Gambardella A, Manganotti P, Melis M, Onofrj M, De Michele G, Reale N, Tedeschi G, Mancardi G.  Coverage of the requirements of first and second level strokeunit in Italy.   Neurol Sci. 2021 Mar;42(3):1073-1079. doi: 10.1007/s10072-020-04616-x.

Boffa G, Massacesi L, Inglese M, Mariottini A, Capobianco M, Lucia M, Amato MP, Cottone S, Gualandi F, De Gobbi M, Greco R, Scimè R, Frau J, Zimatore GB, Bertolotto A, Comi G, Uccelli A, Signori A, Angelucci E, Innocenti C, Ciceri F, Repice AM, Sormani MP, Saccardi R, Mancardi G;  Italian BMT-MS studygroup. Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.  Neurology. 2021 Jan 20:10.1212/WNL.0000000000011461. doi: 10.1212/WNL.0000000000011461.

Capobianco M, Bertolotto A, Malucchi S.  Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case report.  Neurol Sci. 2021 Mar 12. doi: 10.1007/s10072-020-05027-8.

Gnavi R, Picariello R, Alboini PE, Cavalla P, Grasso MF, Richiardi P, Bertolotto A, Barizzone N, Cantello R, Leone MA, D'Alfonso S, Golini N.  Validation of an Algorithm to Detect Multiple Sclerosis Cases in Administrative Health Databases in Piedmont (Italy): An Application to the Estimate of Prevalence by Age and Urbanization Level.  Neuroepidemiology. 2021 Mar 10:1-7. doi: 10.1159/000513763.

Lepore V, Bosetti C, Santucci C, Iaffaldano P, Trojano M, Mosconi P; Bertolotto A; Italian Multiple Sclerosis Register Centers Group, the Scientific Committee of Italian SM Register.  Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register.  Eur J Neurol. 2021 Feb;28(2):567-578. doi: 10.1111/ene.14589. Epub 2020 Nov 6.

Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Trojano M, Zaratin P, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M; Bertolotto A. Musc-19 Study Group.  Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.   Ann Neurol. 2021 Apr;89(4):780-789. doi: 10.1002/ana.26028. Epub 2021 Feb 9.

2020

Masuccio FG, Lo Re M, Bertolotto A, Capobianco M, Solaro C. (2020).  Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.  Mult Scler Relat Disord. Nov;46:102592. doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.

Perga S, Montarolo F, Martire S, Bonaldo B, Bono G, Bertolo J, Magliozzi R, Bertolotto A (2020)  Overexpression of the ubiquitin-editing enzyme A20 in the brain lesions of Multiple Sclerosis patients: moving from systemic to central nervous system inflammation.  Brain Pathology 14:e12906. Oct.DOI: 10.1111/bpa.12906. Online ahead of print.

Bandettini di Poggio M, Toni D, Gandolfo C, Paolicelli D, Zini A, Agostoni E, Bandini F, Ragno M, Altavista MC, Bertolotto A, Siciliano G, Vecchio M, Tambasco N, Gambardella A, Manganotti P, Melis M, Onofrj M, De Michele G, Reale N, Tedeschi G, Mancardi G. (2020)  Coverage of the requirements of first and second level stroke unit in Italy.  Neurol Sci. Jul 31. doi: 10.1007/s10072-020-04616-x. Online ahead of print.

Bertolotto A, Martire S, Mirabile L, Capobianco M, De Gobbi M, Cilloni D. (2020).  Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing-Remitting Multiple Sclerosis Patients . Neurol Ther. Dec;9(2):197-203. doi: 10.1007/s40120-020-00200-9. Epub 2020 Jun 16.

Bertolotto A, Arroyo R, Celius EG, Comi G, Havrdova EK, Honeycutt WD, Hunter SF, Izquierdo G, Kornek B, Miller T, Mitsikostas DD, Singer BA, Ziemssen T, Chung L, Daizadeh N, Afsar S, Hashemi L, Senior P. (2020)  Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies.  Neurol Ther. Dec;9(2):443-457. doi: 10.1007/s40120-020-00191-7. Epub 2020 May 14.

Montarolo F*, Perga S, Tessarolo C, Spadaro M, Martire S, Bertolotto A (2020)  TNFAIP3 Deficiency Affects Monocytes, Monocytes-Derived Cells and Microglia in Mice.  International Journal of Molecular Science21, 2830. DOI:10.3390/ijms21082830

Comi G, Pozzilli C, Morra VB, Bertolotto A, Sangalli F, Prosperini L, Carotenuto A, Iaffaldano P, Capobianco M, Colombo D, Nica M, Rizzoli S, Trojano M. (2020)  Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study.  Neurol Sci. Oct;41(10):2843-2851. doi: 10.1007/s10072-020-04380-y. Epub 2020 Apr 21.

Valsecchi V*, Boido M*, Montarolo F, et al.  The transcription factor Nurr1 is up-regulated in amyotrophic lateral sclerosis patients and SOD1-G93A mice  [published online ahead of print, 2020 Mar 18]. Dis Model Mech. 2020;dmm.043513. doi:10.1242/dmm.043513 - *co-authors

Marangon D, Boda E, Parolisi R, Negri C, Giorgi C, Montarolo F, Perga S, Bertolotto A, Buffo A, Abbracchio MP, Lecca D. (2020)  In vivo silencing of miR-125a-3p promotes myelin repair in models of white matter demyelination.  Glia. Oct;68(10):2001-2014. doi: 10.1002/glia.23819. Epub 2020 Mar 12.

Giordano A, Testa S, Bassi M, Cilia S, Bertolotto A, Quartuccio ME, Pietrolongo E, Falautano M, Grobberio M, Niccolai C, Allegri B, Viterbo RG, Confalonieri P, Giovannetti AM, Cocco E, Grasso MG, Lugaresi A, Ferriani E, Nocentini U, Zaffaroni M, De Livera A, Jelinek G, Solari A, Rosato R. (2020)  Assessing measurement invariance of MSQOL-54 across Italian and English versions.  Qual Life Res. Mar;29(3):783-791. doi: 10.1007/s11136-019-02352-0. Epub 2019 Nov 9.

2019

Spadaro M, Montarolo F, Martire S., Frezet F, Bruno S, Grometto A, Perga S, Brescia F, Valentino P, Marnetto F, Botta G, Marozio L, Bertolotto A. Pregnancy: a powerful transient immunosuppressive phenomenon in Multiple Sclerosis women , Poster presentation at the 2019 FISM Congress, Rome (Italy).

Montarolo F, Martire S, Perga S and Bertolotto A.  NURR1 Impairment in Multiple Sclerosis. Int. J. Mol. Sci. 2019, 20, 4858; doi:10.3390/ijms20194858.

Montarolo F, Perga S, Tessarolo C, Spadaro M, Martire S, Bertolotto A. TNFAIP3 in circulating and parenchymal myeloid lineage critically controls monocytes, monocytes-derived cells and microglia. Journal of Neuroinflammation (submitted).

Giordano A, Testa S, Bassi M, Cilia S, Bertolotto A, Quartuccio ME, Pietrolongo E, Falautano M, Grobberio M, Niccolai C, Allegri B, Viterbo RG, Confalonieri P, Giovannetti AM, Cocco E, Grasso MG, Lugaresi A, Ferriani E, Nocentini U, Zaffaroni M, De Livera A, Jelinek G, Solari A, Rosato R. Assessing measurement invariance of MSQOL-54 across Italian and English versions. Qual Life Res . 2019 Nov 9. doi: 10.1007/s11136-019-02352-0. [Epub ahead of print]

Acknowledgement to Authors, Referees and Readers 2019.
Sabbagh M, Bertolotto A. Neurol Ther. 2019 Dec;8(2):513-515. doi: 10.1007/s40120-019-00163-6. No abstract available.

Spadaro M, Martire S, Marozio L, Mastromauro D, Montanari E, Perga S, Montarolo F, Brescia F, Balbo A, Botta G, Benedetto C, Bertolotto A. Immunomodulatory Effect of Pregnancy on Leukocyte Populations in Patients With Multiple Sclerosis: A Comparison of Peripheral Blood and Decidual Placental Tissue .
Front Immunol. 2019 Aug 16;10:1935. doi: 10.3389/fimmu.2019.01935. eCollection 2019.

Montarolo F, Martire S, Perga S, Spadaro M, Brescia I, Allegra S, De Francia S, Bertolotto A. NURR1 deficiency is associated to ADHD-like phenotypes in mice . Transl Psychiatry. 2019 Aug 27;9(1):207. doi: 10.1038/s41398-019-0544-0.

Romano S, Ferraldeschi M, Bagnato F, Mechelli R, Morena E, Caldano M, Buscarinu MC, Fornasiero A, Frontoni M, Nociti V, Mirabella M, Mayer F, Bertolotto A, Pozzilli C, Vanacore N, Salvetti M, Ristori G. Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority. Front Neurol. 2019 Jul 16;10:695. doi: 10.3389/fneur.2019.00695. eCollection 2019.

Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, Boster A, Celius EG, de Seze J, Cruz DD, Habek M, Lee JM, Limmroth V, Meuth SG, Oreja-Guevara C, Pagnotta P, Vos C, Ziemssen T, Baker DP, Wijmeersch BV. Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. Front Neurol. 2019 Mar 22;10:253. doi: 10.3389/fneur.2019.00253. eCollection 2019. Review.

Sabbagh M, Bertolotto A. Neurology and Therapy: Looking Back on 2018 and Forward to 2019.
Neurol Ther. 2019 Jun;8(1):1-3. doi: 10.1007/s40120-019-0126-3. Epub 2019 Jan 30. No abstract available.

2018

Scarpazza C, Signori A, Prosperini L, Sormani MP, Cosottini M, Capra R, Gerevini S. Italian PML Group. Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution. 2018 ; J Neurol Neurosurg Psychiatry. 2018 Nov 2. IF 7.14 R=36/336

Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group.  No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month realworld study. J Neurol. 2018 Sep 26. IF=3.78

Marcinnò A, Marnetto F, Valentino P, Martire S, Balbo A, Drago A, Leto M, Capobianco M, Panzica G, Bertolotto, A. Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2018 Sep 13;5(6) IF= 6.429; R= 36/336

Bo M, Charrier L, Bartalini S, Benvenuti M, Oggero A, Ulivelli M, Gabbrielli M, Bertolotto A, Gianino MM. Access to social security benefits among multiple sclerosis patients in Italy: A cross-sectional study Mult Scler Relat Disord. 2018 Aug; 24:107-112. IF=4.84¸ R=clinical neurology 91/336

Mallucci G, Annovazzi P, Miante S, Torri-Clerici V, Matta M, La Gioia S, Cavarretta R, Mantero V, Costantini G, D'Ambrosio V, Zaffaroni M, Ghezzi A, Perini P, Rossi S, Bertolotto A, Rottoli MR, Rovaris M, Balgera R, Cavalla P, Montomoli C, Bergamaschi R. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study . J Neurol. 2018 Aug; 265(8):1850-1859. IF= 3.78

Rosato R, Testa S, Bertolotto A, Scavelli F, Giovannetti AM, Confalonieri P, Patti F, Chisari CG, Lugaresi A, Pietrolongo E, Grasso MG, Rossi I, Toscano A, Loera B, Giordano A, Solari A. eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54 . Mult Scler. 2018 May IF= 5.28 R=69/336

Perga S, Martire S, Montarolo F, Giordani I, Spadaro M, Bono G, Corvisieri S, Messuti I, Panzica G, Orlandi F, Bertolotto A. The Footprints of Poly-Autoimmunity: Evidence for Common Biological Factors Involved in Multiple Sclerosis and Hashimoto's Thyroiditis. Front Immunol. 2018 Feb 20; 9:311. IF= 6.429; R= 24/194

Carletto S, Borghi M, Scavelli F, Francone D, Perucchini ML, Cavallo M, Pagnini F, Bertolotto A, Oliva F, Ostacoli L.  Prevalence of Posttraumatic Stress Disorder in Patients With Multiple Sclerosis. J Nerv Ment Dis. 2018 Feb;206(2):149-151. IF= 1.94 R= 167/487

Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents : A Baroncini D, Zaffaroni M, Moiola L, Lorefice L, Fenu G, Iaffaldano P, Simone M, Fanelli F, Patti F, D'Amico E, Capobianco M, Bertolotto A, Gallo P, Margoni M, Miante S, Milani N, Amato MP, Righini I, Bellantonio P, Scandellari C, Costantino G, Scarpini E, Bergamaschi R, Mallucci G, Comi G, Ghezzi A; iMED Registry and Gruppo di Studio SM-Società Italiana di Neurologia. multicentre, Italian, retrospective, observational study. Mult Scler. 2018 Jan 1 IF=5.28 R=69/336

Correction to: Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G. Neurol Sci. 2018 Feb;39(2):395 IF=1.74; R=clinical neurology 169/336

Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia. Trunfio M, Joseph SB, Ghisetti V, Romito A, Martini C, Cusato J, Audagnotto S, Pesci Kincer L, Ferrara M, Sala A, Imperiale D, Di Perri G, Calcagno A. J Neurovirol. 2018 Feb;24(1):132-136 1 IF=3.22 R= 58/336

2017

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468.

Valentino P, Marnetto F, Granieri L, Capobianco M, Bertolotto A. Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study. Neurol Neuroimmunol Neuroinflamm 2017;4:e317; doi: 10.1212/ NXI.0000000000000317  PMID: 28054001

Clemente N, Comi C, Raineri D, Cappellano G, Vecchio D, Orilieri E, Gigliotti CL, Boggio E, Dianzani C, Sorosina M, Martinelli-Boneschi F, Caldano M, Bertolotto A, Ambrogio L, Sblattero D, Cena T, Leone M, Dianzani U and Chiocchetti A (2017)  Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Front. Immunol. 8:321. doi: 10.3389/fimmu.2017.00321

Melillo F, Di Sapio A, Martire S, Malentacchi M, Matta M, Bertolotto A. Computerized posturography is more sensitive than clinical Romberg Test in detecting postural control impairment in minimally impaired Multiple Sclerosis patients. Mult Scler and Rel Dis, 14:51-55, 2017 ISSN 2211-0348, http://doi.org/10.1016/j.msard.2017.03.008 .

Malucchi S, Capobianco M, Lo Re M, Malentacchi M, di Sapio A, Matta M, Sperli F, Bertolotto A  High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study. Neurol Ther. 2017 Jun;6(1):145-152. doi: 10.1007/s40120-016-0058-0. Epub 2016 Dec 3. PMID: 27915429

Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D; Italian PML study group. Collaborators: Amato MP, Bandini F, Bertolotto A, Brescia-Morra V, Cavaletti G, Cavalla P, Capobianco M, Clerico M, D'Aleo G, de Riz M, Deotto L, Durelli L, Falcini M, Ferrari E, Fusco ML, Gasperini C, Gerevini S, Ghezzi A, Grimaldi L, Guidotti M, Lugaresi A, Naldi P, Moiola L, Perrone P, Pizzorno M, Pozzilli C, Rezzonico M, Rovaris M, Salemi G, Salvetti M, Santuccio G, Scarpini E, Sessa E, Solaro C, Tabiadon G, Tortorella C, Trojano M  No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology. 2017 Mar 21;88(12):1144-1152. doi: 10.1212/WNL.0000000000003740 PMID: 28228569

Marnetto F, Valentino P, Caldano M, Bertolotto A. Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients.   J Immunol Methods. 2017 Mar 12. pii: S0022-1759(16)30395-7. doi: 10.1016/j.jim.2017.03.008. [Epub ahead of print] PMID: 28300540

Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry. Prognostic indicators in pediatric clinically isolated syndrome. Ann Neurol. 2017 May;81(5):729-739. doi: 10.1002/ana.24938. PMID: 28439957

Spadaro M, Montarolo F, Perga S, Martire S, Brescia F, Malucchi S, Bertolotto A Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10 years in responder multiple sclerosis patients Clin Immunol 181 (2017) 83–88 doi: 10.1016/j.clim.2017.06.006. PMID: 28642148

Gils A, Bertolotto A, Mulleman D, Bejan-Angoulvant T, Declerck PJ. Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases. Ther Drug Monit. 2017 Aug;39(4):308-315. doi: 10.1097/FTD.0000000000000385. PMID: 28230618

Paintaud G, Passot C, Ternant D, Bertolotto A, Bejan-Angoulvant T, Pascual-Salcedo D, Mulleman D. Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases. Ther Drug Monit. 2017 Aug;39(4):339-343. doi: 10.1097/FTD.0000000000000410. PMID: 28486309

Caldano M, Raoul W, Rispens T, Bertolotto A. Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological Agents.   Ther Drug Monit. 2017 Aug;39(4):350-355. doi: 10.1097/FTD.0000000000000393. PMID: 28328761

Carletto S, Tesio V, Borghi M, Francone D, Scavelli F, Bertino G, Malucchi S, Bertolotto A, Oliva F, Torta R, Ostacoli L. (2017)  The Effectiveness of a Body-Affective Mindfulness Intervention for Multiple Sclerosis Patients with Depressive Symptoms: A Randomized Controlled Clinical Trial.  Front Psychol. Nov 30;8:2083. IF= 2.32; R=33/129

Rocca MA, Sormani MP, Rovaris M, Caputo D, Ghezzi A, Montanari E, Bertolotto A, Laroni A, Bergamaschi R, Martinelli V, Comi G, Filippi M. (2017)  Long-term disability progression in primary progressive multiple sclerosis: a 15-year study.  Brain Nov 1;140(11):2814-2819.

Franciotta D, Gastaldi M, Sala A, Andreetta F, Rinaldi E, Ruggieri M, Leante R, Costa G, Biagioli T, Massacesi L, Bazzigaluppi E, Fazio R, Mariotto S, Ferrari S, Galloni E, Perini F, Zardini E, Zuliani L, Zoccarato M, Giometto B, Bertolotto A. (2017).  Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD).  Neurol Sci. 2017 Oct;38(Suppl 2) Review.

Gastaldi M, Zardini E, Leante R, Ruggieri M, Costa G, Cocco E, De Luca G, Cataldo I, Biagioli T, Ballerini C, Castellazzi M, Fainardi E, Pettini P, Zaffaroni M, Giunti D, Capello E, Bernardi G, Ciusani E, Giannotta C, Nobile-Orazio E, Bazzigaluppi E, Passerini G, Bedin R, Sola P, Brivio R, Cavaletti G, Sala A, Bertolotto A, Desina G, Leone MA, Mariotto S, Ferrari S, Paternoster A, Giavarina D, Lolli F, Franciotta D. (2017).  Cerebrospinal fluid analysis and the determination of oligoclonal bands.  Neurol Sci. Oct;38(Suppl 2):217-22. Review

Ghezzi A, Bianchi A, Baroncini D, Bertolotto A, Malucchi S, Bresciamorra V, Lanzillo R, Milani N, Martinelli V, Patti F, Chisari C, Rottoli M, Simone M, Paolicelli D, Visconti A; FUTURE Study Group. (2017).  A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study.  Neurol Sci. Nov;38(11):1999-2005.

Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G. (2017).  Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.  Neurol Sci. Oct;38(10) Erratum in: Neurol Sci. 2017 Dec 26

Annovazzi P, Bertolotto A, Brescia Morra V, Gasperini C, Montanari E, Navarra P, Patti F, Sormani MP, Ghezzi A. (2017)  A Comprehensive Review on Copemyl®.  Neurol Ther.Dec;6(2):161-173. Review R=94/138

2016

Bertolotto A, Malentacchi M, Capobianco M, di Sapio A, Malucchi S, Motuzova Y, Pulizzi A, Berchialla P, Sperli F  The use of the 25 Sprotte needle markedly reduces post-dural puncture headache in routine neurological practice Cephalalgia 2016, 36: 131-138, doi:10.1177/0333102415583983

Carletto S, Borghi M, Francone D, Scavelli F, Bertino G, Cavallo M, Malucchi S, Bertolotto A, Oliva F, Ostacoli L. The efficacy of a Mindfulness Based Intervention for depressive symptoms in patients with Multiple Sclerosis and their caregivers: study protocol for a randomized controlled clinical trial. BMC Neurol. 2016 Jan 13;16(1):7. doi: 10.1186/s12883-016-0528-0. ISSN: 14712377 PMID: 26757728

Martire S, Navone ND, Montarolo F, Perga S, Bertolotto A. A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients. J Neuroimmunol. 2016 Mar 15;292:34-9. doi: 10.1016/j.jneuroim.2016.01.010. Epub 2016 Jan 16. PMID: 26943956

Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 12;387(10023):1075-84. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28

Rosato R, Testa S, Bertolotto A, Confalonieri P, Patti F, Lugaresi A, Grasso MG, Toscano A, Giordano A, Solari A. Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory. PLoS One. 2016 Apr 14;11(4):e0153466. doi: 10.1371/journal.pone.0153466. eCollection 2016. PMID: 27078146

Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Fazekas F, Killestein J, Lindberg RL, Malucchi S, Mehling M, Montalban X, Rudzki D, Schautzer F, Sellebjerg F, Sorensen PS, Deisenhammer F, Steinman L, Axtell RC. Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e202. doi: 10.1212/NXI.0000000000000202. eCollection 2016 Apr PMID: 26894205

Troni W, Melillo F, Bertolotto A, Malucchi S, Capobianco M, Sperli F, Di Sapio A.  Normative Values for Intertrial Variability of Motor Responses to Nerve Root and Transcranial Stimulation: A Condition for Follow-Up Studies in Individual Subjects PLoS One. 2016 May 16;11(5):e0155268. doi: 10.1371/journal.pone.0155268. eCollection 2016. PMID: 27182973

Borghi M, Carletto S, Ostacoli L, Scavelli F, Pia L, Pagani M, Bertolotto A, Malucchi S, Signori A, Cavallo M. Decline of Neuropsychological Abilities in a Large Sample of Patients with Multiple Sclerosis: A Two-Year Longitudinal Study. Front Hum Neurosci. 2016 Jun 8;10:282. doi: 10.3389/fnhum.2016.00282. eCollection 2016. PMID: 27375468

Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H. PML risk stratification using anti-JCV antibody index and L-selectin.  Mult Scler. 2016 Jul;22(8):1048-1060. Epub 2015 Oct 2. PMID: 26432858

Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, Francia A, Florio C, Orefice G, Tedeschi G, Bellantonio P, Annunziata P, Grimaldi LM, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Brescia Morra V; ARIANNA study group. No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1a therapy in relapsing-remitting multiple sclerosis (the ARIANNA study) . Mult Scler. 2016 Aug;22(9):1163-73. doi: 10.1177/1352458515611222. Epub 2015 Oct 14. PMID: 26466947

Waters P, Reindl M, Saiz A, Schanda K, Tuller F, Kral V, Nytrova P, Sobek O, Nielsen HH, Barington T, Lillevang ST, Illes Z, Rentzsch K, Berthele A, Berki T, Granieri L, Bertolotto A, Giometto B, Zuliani L, Hamann D, van Pelt ED, Hintzen R, Höftberger R, Costa C, Comabella M, Montalban X, Tintoré M, Siva A, Altintas A, Deniz G, Woodhall M, Palace J, Paul F, Hartung HP, Aktas O, Jarius S, Wildemann B, Vedeler C, Ruiz A, Leite MI, Trillenberg P, Probst M, Saschenbrecker S, Vincent A, Marignier R. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):1005-15. doi: 10.1136/jnnp-2015-312601. PMID: 27113605

Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, Bruno Bossio R, Brescia Morra V, Costantino GF, Cavalla P, Centonze D, Comi G, Cottone S, Danni M, Francia A, Gajofatto A, Gasperini C, Ghezzi A, Iudice A, Lus G, Maniscalco GT, Marrosu MG, Matta M, Mirabella M, Montanari E, Pozzilli C, Rovaris M, Sessa E, Spitaleri D, Trojano M, Valentino P, Zappia M; SA.FE. study group. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):944-51. doi: 10.1136/jnnp-2015-312591. Epub 2016 May 9. PMID: 27160523

Montarolo F, Perga S, Martire S, Navone DN, Marchet A, Leotta D, Bertolotto A. Altered NR4A Subfamily Gene Expression Level in Peripheral Blood of Parkinson's and Alzheimer's Disease Patients. Neurotox Res. 2016 Oct;30(3):338-44. doi: 10.1007/s12640-016-9626-4. Epub 2016 May 9. PMID: 27159982

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology. 2016 Nov 8;87(19):1985-1992. PMID: 27733571

Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, Hartung HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL, Lake SL, Margolin DH, Thomas DR, Panzara MA, Compston DA; CARE-MS I and CARE-MS II Investigators. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS. Neurology 2016 Oct 4;87(14):1464-1472 PMID: 27590291 PMCID: PMC5075976 DOI: 10.1212/WNL.0000000000003169

Chiavazza C, Cistaro A, Fania P, Bertolotto A, Cavalla P, Rudà R, Pinessi L, Soffietti R Reversible disconnection syndrome in a case of acute tumefactive demyelinating lesion: a PET study. Neurol Sci. 2016 Dec;37(12):2019-2023  PMID: 27457655

Marola S, Ferrarese A, Gibin E, Capobianco M, Bertolotto A, Enrico S, Solej M, Martino V, Destefano I, Nan. o M. Anal sphincter dysfunction in multiple sclerosis: an observation manometric study. Open Med. 2016; 11: 509-517DOI 10.1515/med-2016-0088